Swedish Orphan Biovitrum AB (publ)
STO:SOBI

Watchlist Manager
Swedish Orphan Biovitrum AB (publ) Logo
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Watchlist
Price: 290 SEK -0.21% Market Closed
Market Cap: 99.8B SEK
Have any thoughts about
Swedish Orphan Biovitrum AB (publ)?
Write Note

Swedish Orphan Biovitrum AB (publ)
PP&E Net

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Swedish Orphan Biovitrum AB (publ)
PP&E Net Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Net CAGR 3Y CAGR 5Y CAGR 10Y
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
PP&E Net
kr384m
CAGR 3-Years
-7%
CAGR 5-Years
-5%
CAGR 10-Years
13%
Biogaia AB
STO:BIOG B
PP&E Net
kr213.3m
CAGR 3-Years
9%
CAGR 5-Years
15%
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
PP&E Net
kr20.6m
CAGR 3-Years
11%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Vitrolife AB
STO:VITR
PP&E Net
kr391m
CAGR 3-Years
35%
CAGR 5-Years
17%
CAGR 10-Years
16%
Probi AB
STO:PROB
PP&E Net
kr237.8m
CAGR 3-Years
22%
CAGR 5-Years
20%
CAGR 10-Years
61%
BioArctic AB
STO:BIOA B
PP&E Net
kr31.1m
CAGR 3-Years
-8%
CAGR 5-Years
27%
CAGR 10-Years
N/A
No Stocks Found

Swedish Orphan Biovitrum AB (publ)
Glance View

Market Cap
99.6B SEK
Industry
Biotechnology

Swedish Orphan Biovitrum AB (publ), often referred to as Sobi, is a biopharmaceutical company that has carved a niche in the development and commercialization of innovative treatments for rare diseases, primarily focusing on hematology, immunology, and specialty care. Founded in 2001 and headquartered in Stockholm, Sobi has garnered a reputation for its commitment to improving the lives of patients with complex medical conditions. The company's portfolio includes several key products that address unmet medical needs, particularly in areas such as hemophilia and other inherited disorders. Through strategic partnerships and acquisitions, Sobi has expanded its capabilities, bolstering its research and development pipeline while strengthening its market presence across Europe, North America, and beyond. As an investor, Sobi presents a compelling opportunity in the growing field of rare diseases, bolstered by a robust regulatory framework that often allows for expedited approval processes for groundbreaking therapies. The company’s focus on precision medicine and its dedication to patient-centric care position it well in an industry characterized by high demand and limited competition. With a solid financial foundation and a proactive approach to innovation, Sobi is poised to capture significant market share in a rapidly evolving landscape. Furthermore, with its strategic initiatives in expanding global reach and investing in next-generation therapies, Sobi exemplifies the principles of value investing by aligning long-term growth potential with the increasing need for specialized medical treatments.

SOBI Intrinsic Value
368.27 SEK
Undervaluation 21%
Intrinsic Value
Price

See Also

What is Swedish Orphan Biovitrum AB (publ)'s PP&E Net?
PP&E Net
384m SEK

Based on the financial report for Sep 30, 2024, Swedish Orphan Biovitrum AB (publ)'s PP&E Net amounts to 384m SEK.

What is Swedish Orphan Biovitrum AB (publ)'s PP&E Net growth rate?
PP&E Net CAGR 10Y
13%

Over the last year, the PP&E Net growth was 45%. The average annual PP&E Net growth rates for Swedish Orphan Biovitrum AB (publ) have been -7% over the past three years , -5% over the past five years , and 13% over the past ten years .

Back to Top